Industry News
MiReven gets extra $500k for microRNA cancer research
Start-up MiReven has received a $500,000 funding injection, after forging R&D partnerships and reaching internal milestones in efforts to develop cancer treatments based on a strain of microRNA. [ + ]
Trial of NovoSorb hit with delays: Calzada
Calzada (ASX:CZD) has been forced to push back the planned completion date for a planned human clinical trial of its NovoSorb BTM burns treatment product until well into 2013. [ + ]
Court calls meeting to vote on Alchemia spinoff
Alchemia (ASX:ACL) has reached two new milestones in its efforts to spin off its oncology business into a separate company listed on the Nasdaq. [ + ]
Patrys raises cash, shaves loss in FY12
Patrys (ASX:PAB) ended FY12 in a more stable financial position, after raising enough cash to see it through until early 2014. [ + ]
Business Tax Working Group discusses cuts to R&D Tax Incentive
AusBiotech invites members’ comments on the recently released Business Tax Working Group (BTWG) discussion paper, which includes amongst its issues for discussion four options that seek to limit the R&D Tax Incentive to companies with turnover over $20 million. [ + ]
GI Dynamics gets FDA provisional nod for pivotal EndoBarrier trial
The US FDA has provisionally cleared GI Dynamics (ASX:GID) to jump straight to a full clinical trial of EndoBarrier to treat Type 2 diabetes patients who are obese. [ + ]
National citizen science project: are you a binge listener?
The National Acoustic Laboratories, the Hearing CRC and the ABC have teamed up as part of National Science Week to run Sound Check Australia, the national noise and hearing survey, and are giving participants a chance to win $1000 worth of concert tickets. [ + ]
Mesoblast stem cell R&D spend triples
Mesoblast (ASX:MSB) has reinvested a sizeable chunk of the revenues from its licensing deal with Cephalon into boosting research and development efforts for its adult stem cell technology, bumping up total expenses by more than $58 million in FY12. [ + ]
Oncology start-up Senz gets seed funding for chemo agent
Start-up Senz Oncology has secured seed funding to support the development of a chemotherapeutic agent as a potential treatment for acute leukaemias. [ + ]
CSL lifts FY12 profit to US$1 billion
CSL (ASX:CSL) grew its FY12 net profit 4.5% to $983 million, despite taking a significant hit on exchange rates. [ + ]
Researchers develop DNA sequencing tests for hereditary diseases
Scientists at the University of Medicine and Dentistry of New Jersey-New Jersey Medical School (UMDNJ-NJMS) have developed DNA sequencing tests that hold significant promise for decreasing costs associated with diagnosing cancer and hereditary diseases, including cystic fibrosis. [ + ]
Advances in decades-old dream of mining seawater for uranium
Scientists have reported progress towards a 40-year-old dream of extracting uranium for nuclear power from seawater, which holds at least four billion tonnes of the precious material. [ + ]
Call to boycott killer robots
Engineers should stop working on killer robots and kick the habit of military funding, a leading Australian applied ethicist has said. [ + ]
Novasys appointed Isocolor distributor
Novasys has recently been appointed sole and exclusive distributor for Australia for the Isocolor range of colour quality control and colour formulation software products. [ + ]
Science in the blood: L’Oreal Fellowship awarded to WEHI’s Kylie Mason
One of the three L’Oreal Fellowships has been awarded to Dr Kylie Mason for her work understanding the relationship between cancer and blood. [ + ]